Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in Primary Antiphospholipid Syndrome (AnifAPS)
NCT07584083Phase 2Recruiting
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anifrolumab in antiphospholipid syndrome (APS), sponsored by National and Kapodistrian University of Athens. Started Apr 2026; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT07584083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584083.